| |
| |
| |
|
|
AN ACT
|
|
|
relating to a study on the use of alternative therapies for treating |
|
|
post-traumatic stress disorder. |
|
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
|
SECTION 1. (a) In this Act, "commission" means the Health |
|
|
and Human Services Commission. |
|
|
(b) The commission, in collaboration with Baylor College of |
|
|
Medicine and in partnership with a military veterans hospital or a |
|
|
medical center that provides medical care to veterans, shall |
|
|
conduct a study on the efficacy of using alternative therapies, |
|
|
including the use of 3,4-methylenedioxymethamphetamine (MDMA), |
|
|
psilocybin, and ketamine, in the treatment of veterans who suffer |
|
|
from post-traumatic stress disorder. |
|
|
(c) In conducting the study described by Subsection (b) of |
|
|
this section, the commission in collaboration with the Baylor |
|
|
College of Medicine shall: |
|
|
(1) perform a clinical trial on the therapeutic |
|
|
efficacy of using psilocybin in the treatment of |
|
|
treatment-resistant post-traumatic stress disorder in veterans; |
|
|
and |
|
|
(2) review current literature regarding: |
|
|
(A) the safety and efficacy of |
|
|
3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and |
|
|
ketamine in the treatment of post-traumatic stress disorder; and |
|
|
(B) the access veterans have to |
|
|
3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and |
|
|
ketamine for treatment of post-traumatic stress disorder in the |
|
|
United States. |
|
|
(d) The commission shall prepare and submit to the governor, |
|
|
the lieutenant governor, the speaker of the house of |
|
|
representatives, and each member of the legislature: |
|
|
(1) quarterly reports on the progress of the study |
|
|
conducted under this section; and |
|
|
(2) not later than December 1, 2024, a written report |
|
|
containing the results of the study conducted under this section |
|
|
and any recommendations for legislative or other action. |
|
|
(e) The commission shall ensure any protected health |
|
|
information collected during a clinical trial conducted under |
|
|
Subsection (c) of this section and reported under Subsection (d) of |
|
|
this section does not personally identify an individual. |
|
|
(f) This Act expires September 1, 2025. |
|
|
SECTION 2. The Agency is required to implement this Act only |
|
|
if the legislature appropriates money specifically for that |
|
|
purpose. If the legislature does not appropriate money |
|
|
specifically for that purpose, the commission may, but is not |
|
|
required to, implement this Act using other appropriations |
|
|
available for the purpose. |
|
|
SECTION 3. This Act takes effect immediately if it receives |
|
|
a vote of two-thirds of all the members elected to each house, as |
|
|
provided by Section 39, Article III, Texas Constitution. If this |
|
|
Act does not receive the vote necessary for immediate effect, this |
|
|
Act takes effect September 1, 2021. |
| |
| |
| |
______________________________ |
______________________________ |
| |
President of the Senate |
Speaker of the House |
| |
| |
|
|
I certify that H.B. No. 1802 was passed by the House on May 6, |
|
|
2021, by the following vote: Yeas 134, Nays 12, 1 present, not |
|
|
voting; and that the House concurred in Senate amendments to H.B. |
|
|
No. 1802 on May 28, 2021, by the following vote: Yeas 134, Nays 9, |
|
|
2 present, not voting. |
|
|
|
|
|
______________________________ |
|
|
Chief Clerk of the House |
| |
|
|
I certify that H.B. No. 1802 was passed by the Senate, with |
|
|
amendments, on May 22, 2021, by the following vote: Yeas 25, Nays |
|
|
5. |
|
|
|
|
|
______________________________ |
|
|
Secretary of the Senate |
|
|
APPROVED: __________________ |
|
|
Date |
|
|
|
|
|
__________________ |
|
|
Governor |